{"id":536114,"date":"2021-09-09T07:03:49","date_gmt":"2021-09-09T11:03:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-09T07:03:49","modified_gmt":"2021-09-09T11:03:49","slug":"aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MENLO PARK, Calif. and SINGAPORE, Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021.<\/p>\n<p>An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Um08gD5_PEVpwQfSD6wX7VEwDMKOVoJnH_a6yDproT-mXi1GuOIgHpaPHOroXWC1IhvfQPxBn_it773K05UUpq9KUSTi_K1auj9W7HK91tw=\" rel=\"nofollow noopener\" target=\"_blank\">www.ir.aslanpharma.com<\/a> and at the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RjttufwRwTxpJNvvphJJWfSWXoHeId3mLxzLzZtWzYMV9hqMdcD62vdUIj1ST91yu7Xrdu3i4WRNmwOnrZ0QF3tVo6FY4K03XRBcOSyMG9PFcRhROLq5pVNiCTm0dtZaEf3Vc7nFMG6tYECnl_bwR2UHG5y83t6YSS5bd1oIMSNtK4PHPJ2m3qIhvrxUvQyDtiFEz1vRYXcmiNajssuUBg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/journey.ct.events\/view\/1b10cdbc-a1e0-4f84-b475-753e1832a13a<\/a><\/p>\n<p>\n        <strong>Media and IR contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:40%;width:40%;min-width:40%;vertical-align: top\">\n            <strong>Emma Thompson<\/strong><br \/>\n            <br \/>Spurwing Communications<br \/>Tel: +65 6206 7350<br \/>Email: <a href=\"mailto:ASLAN@spurwingcomms.com\" rel=\"nofollow noopener\" target=\"_blank\">ASLAN@spurwingcomms.com<\/a><\/td>\n<td style=\"max-width:60%;width:60%;min-width:60%;vertical-align: top\">\n            <strong>Ashley R. Robinson<\/strong><br \/>\n            <br \/>LifeSci Advisors, LLC<br \/>Tel: +1 (617) 430-7577 <br \/>Email: <a href=\"mailto:arr@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">arr@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About ASLAN Pharmaceuticals<\/strong><br \/>\n        <br \/>ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN\u00a0is currently evaluating\u00a0ASLAN004, a\u00a0potential first-in-class\u00a0antibody\u00a0targeting the IL-13 receptor,\u00a0in atopic dermatitis, and ASLAN003,\u00a0a\u00a0potent oral\u00a0inhibitor\u00a0of\u00a0DHODH, which is being developed for\u00a0autoimmune disease.\u00a0ASLAN has a team in Menlo Park, California, and in Singapore.\u00a0For additional information please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w8Ciy8mRndWkW1HIjYIck088JwQOHz0joXBY6o-h1PiiKbQJRFW5hTVXQxk80688PAVfYRGHVc8SJMZ5lSXsVwW0belqXFKXnDSRB-i6gaE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.aslanpharma.com<\/u><\/a>\u00a0or follow\u00a0ASLAN\u00a0on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F8_f8wt0MoP97F6Gr2MZB0bxgIXkTku1arQFkulumF531z58utpEvCWIrP_Bjl-BZx9iA1zYml45FWuzcd7NHZqbNoZSywb8AtSP5ZYK8_Z_7St5LWrvoieb5wCzP6aEf1v5xi4cTEXeBv8mM4PCOQ==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzU5M2YzZGQtYTc1ZS00M2Y1LTlmMDMtMWM2YTcyMTViNzBiLTExMDcwNjI=\/tiny\/ASLAN-PHARMACEUTICALS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021. An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN\u2019s website at www.ir.aslanpharma.com and at the following link: https:\/\/journey.ct.events\/view\/1b10cdbc-a1e0-4f84-b475-753e1832a13a Media and IR contacts Emma Thompson Spurwing CommunicationsTel: +65 6206 7350Email: ASLAN@spurwingcomms.com Ashley R. Robinson LifeSci Advisors, LLCTel: +1 (617) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536114","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021. An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN\u2019s website at www.ir.aslanpharma.com and at the following link: https:\/\/journey.ct.events\/view\/1b10cdbc-a1e0-4f84-b475-753e1832a13a Media and IR contacts Emma Thompson Spurwing CommunicationsTel: +65 6206 7350Email: ASLAN@spurwingcomms.com Ashley R. Robinson LifeSci Advisors, LLCTel: +1 (617) &hellip; Continue reading &quot;ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T11:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-09T11:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":226,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=\",\"datePublished\":\"2021-09-09T11:03:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021. An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN\u2019s website at www.ir.aslanpharma.com and at the following link: https:\/\/journey.ct.events\/view\/1b10cdbc-a1e0-4f84-b475-753e1832a13a Media and IR contacts Emma Thompson Spurwing CommunicationsTel: +65 6206 7350Email: ASLAN@spurwingcomms.com Ashley R. Robinson LifeSci Advisors, LLCTel: +1 (617) &hellip; Continue reading \"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T11:03:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-09T11:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":226,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=","datePublished":"2021-09-09T11:03:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzA3MSM0Mzk3MTQ2IzIwOTU0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536114"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536114\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}